Squarepoint Ops LLC Purchases 20,805 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE)

Squarepoint Ops LLC increased its position in shares of Fate Therapeutics, Inc. (NASDAQ:FATE) by 154.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 34,295 shares of the biopharmaceutical company’s stock after purchasing an additional 20,805 shares during the period. Squarepoint Ops LLC’s holdings in Fate Therapeutics were worth $57,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the stock. Graham Capital Management L.P. acquired a new stake in shares of Fate Therapeutics in the 4th quarter valued at $37,000. Brevan Howard Capital Management LP acquired a new stake in shares of Fate Therapeutics in the 4th quarter valued at $41,000. FPC Investment Advisory Inc. acquired a new stake in shares of Fate Therapeutics in the 4th quarter valued at $44,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Fate Therapeutics in the 4th quarter valued at $55,000. Finally, ProShare Advisors LLC boosted its stake in shares of Fate Therapeutics by 77.9% in the 4th quarter. ProShare Advisors LLC now owns 33,645 shares of the biopharmaceutical company’s stock valued at $56,000 after purchasing an additional 14,728 shares in the last quarter. 97.54% of the stock is currently owned by institutional investors.

Fate Therapeutics Stock Up 9.9%

Fate Therapeutics stock opened at $1.67 on Wednesday. Fate Therapeutics, Inc. has a 12-month low of $0.66 and a 12-month high of $5.92. The business’s 50-day moving average price is $1.16 and its two-hundred day moving average price is $1.38. The stock has a market cap of $191.39 million, a PE ratio of -1.01 and a beta of 2.23.

Fate Therapeutics (NASDAQ:FATE) last released its earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.07. Fate Therapeutics had a negative return on equity of 45.88% and a negative net margin of 1,325.43%. The firm had revenue of $1.63 million for the quarter, compared to analysts’ expectations of $1.18 million. As a group, analysts expect that Fate Therapeutics, Inc. will post -1.63 earnings per share for the current year.

Analysts Set New Price Targets

FATE has been the topic of several research reports. Wedbush reiterated a “neutral” rating and set a $5.00 price target on shares of Fate Therapeutics in a research report on Thursday, March 6th. Needham & Company LLC reiterated a “hold” rating on shares of Fate Therapeutics in a research report on Wednesday, May 14th. Robert W. Baird dropped their price objective on Fate Therapeutics from $5.00 to $4.00 and set a “neutral” rating for the company in a report on Wednesday, May 14th. Wall Street Zen raised Fate Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, May 15th. Finally, Wells Fargo & Company dropped their price objective on Fate Therapeutics from $5.00 to $4.00 and set an “equal weight” rating for the company in a report on Thursday, March 6th. Eight equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, Fate Therapeutics presently has a consensus rating of “Hold” and an average target price of $4.14.

Fate Therapeutics Profile

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.